The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2019 | DLL3, a new biomarker for neuroendocrine tumors of the lung
Alex Haragan, BSc, MBBS, MSc, of the University of Liverpool, Liverpool, UK, discusses the emergence of DLL3 as a biomarker and therapeutic target in neuroendocrine tumors of the lung. The antibody-drug conjugate rovalpituzumab tesirine has been developed to target this tumor-specific antigen, although there have been some issues with toxicity. However, as emphasized here by Dr Haragan, this population is in desperate need of new treatments. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland.
